Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04291105 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
A Phase 2 study of Colorectal Cancer and Melanoma, sponsored by Vyriad.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT04291105: Recruiting Phase 2 study of Colorectal Cancer and Melanoma, sponsored by Vyriad.
NCT04291105 is a Phase 2 study of Colorectal Cancer and Melanoma that is actively recruiting participants, run by Vyriad. The registered enrollment target is 87 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04291105, a Phase 2 study of Colorectal Cancer and Melanoma, is actively recruiting participants, sponsored by Vyriad.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Primary Outcome
Percentage of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through disease progression, by investigator review based on RECIST version 1.1
Conditions Studied
Interventions
- BIOLOGICAL Cemiplimab
- BIOLOGICAL VV1
Study Locations (20)
California
- City of Hope Medical Center - Durate
- USC Norris Comprehensive Cancer Center - Los Angeles
- HOAG Memorial Hospital Presbyterian - Newport Beach
- Saint John's Health Center - John Wayne Cancer Institute (JWCI) - Santa Monica
- Stanford Health Care - Stanford
Florida
- Mayo Clinical - Jacksonville
- University of Miami - Miami
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
New Jersey
- Atlantic Health - Morristown
- Rutgers Cancer Institute of New Jersey - New Brunswick
Ohio
- University of Cincinnati Medical Center - Cincinnati
- Ohio State University - Columbus
Arizona
- Mayo Clinical - Phoenix
Connecticut
- Yale University - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT04291105 shows while recruiting
NCT04291105 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT04291105 names 20 study sites across 12 states, led by California, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04291105 about?
NCT04291105 is a clinical study titled "Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients". This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are ...
What is the current status of trial NCT04291105?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2020-04-24. Estimated completion is 2025-12.
What conditions does trial NCT04291105 study?
This clinical trial studies the following conditions: Colorectal Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04291105?
The interventions under investigation include: Cemiplimab (BIOLOGICAL), VV1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04291105?
This trial is sponsored by Vyriad, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04291105 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04291105's enrollment target sits among peer trials
87 227th of 381 higher than 155 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- NCT05635643 · 87 participants · Phase 1
Study of CHS-114 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI